Immunotherapy Combination in HER2-Positive Breast Cancer
Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.
Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.
In patients that were PD-L1 positive, there was a significant difference in overall survival compared to PD-L1-negative patients. Kalinsky says that this poses the question of whether there is a small amount of patients that really respond to immunotherapy in this population.
Kalinsky also noted that it was interesting to see higher rates of stromal tumor-infiltrating lymphocytes in the PD-L1-positive cohort, where these lymphocytes seemed to be able to dichotomize those that would respond.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
